224 related articles for article (PubMed ID: 10979978)
1. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
[TBL] [Abstract][Full Text] [Related]
2. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts.
Nimmanapalli R; O'Bryan E; Bhalla K
Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726
[TBL] [Abstract][Full Text] [Related]
3. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
Soga S; Neckers LM; Schulte TW; Shiotsu Y; Akasaka K; Narumi H; Agatsuma T; Ikuina Y; Murakata C; Tamaoki T; Akinaga S
Cancer Res; 1999 Jun; 59(12):2931-8. PubMed ID: 10383157
[TBL] [Abstract][Full Text] [Related]
4. Radicicol-mediated inhibition of Bcr-Abl in K562 cells induced p38-MAPK dependent erythroid differentiation and PU.1 down-regulation.
Morceau F; Buck I; Dicato M; Diederich M
Biofactors; 2008; 34(4):313-29. PubMed ID: 19850986
[TBL] [Abstract][Full Text] [Related]
5. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
[TBL] [Abstract][Full Text] [Related]
6. Stereospecific antitumor activity of radicicol oxime derivatives.
Soga S; Sharma SV; Shiotsu Y; Shimizu M; Tahara H; Yamaguchi K; Ikuina Y; Murakata C; Tamaoki T; Kurebayashi J; Schulte TW; Neckers LM; Akinaga S
Cancer Chemother Pharmacol; 2001 Dec; 48(6):435-45. PubMed ID: 11800023
[TBL] [Abstract][Full Text] [Related]
7. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Wu LX; Xu JH; Zhang KZ; Lin Q; Huang XW; Wen CX; Chen YZ
Leukemia; 2008 Jul; 22(7):1402-9. PubMed ID: 18418407
[TBL] [Abstract][Full Text] [Related]
8. [The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine].
Sun JR; Zhang XH; He ZW; Gu Y; Yu YZ; Fang YM; Lü QH; Dong QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2246-51. PubMed ID: 17064567
[TBL] [Abstract][Full Text] [Related]
9. Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
Sato S; Honma Y; Hozumi M; Hayashi Y; Matsuo Y; Shibata K; Omura S; Hino K; Tomoyasu S; Tsuruoka N
Leuk Res; 1994 Mar; 18(3):221-8. PubMed ID: 8139288
[TBL] [Abstract][Full Text] [Related]
10. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Okabe M; Uehara Y; Miyagishima T; Itaya T; Tanaka M; Kuni-Eda Y; Kurosawa M; Miyazaki T
Blood; 1992 Sep; 80(5):1330-8. PubMed ID: 1515646
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of p210(bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90.
Wu LX; Xu JH; Huang XW; Zhang KZ; Wen CX; Chen YZ
Acta Pharmacol Sin; 2006 Jun; 27(6):694-9. PubMed ID: 16723087
[TBL] [Abstract][Full Text] [Related]
12. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.
An WG; Schulte TW; Neckers LM
Cell Growth Differ; 2000 Jul; 11(7):355-60. PubMed ID: 10939589
[TBL] [Abstract][Full Text] [Related]
13. Development of radicicol analogues.
Soga S; Shiotsu Y; Akinaga S; Sharma SV
Curr Cancer Drug Targets; 2003 Oct; 3(5):359-69. PubMed ID: 14529387
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
Schulte TW; Akinaga S; Soga S; Sullivan W; Stensgard B; Toft D; Neckers LM
Cell Stress Chaperones; 1998 Jun; 3(2):100-8. PubMed ID: 9672245
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
[TBL] [Abstract][Full Text] [Related]
16. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.
Okabe M; Kunieda Y; Miyagishima T; Kobayashi M; Kurosawa M; Itaya T; Sakurada K; Miyazaki T
Leuk Lymphoma; 1993 Jul; 10(4-5):307-16. PubMed ID: 7693103
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
Kawano T; Horiguchi-Yamada J; Iwase S; Furukawa Y; Kano Y; Yamada H
Mol Cell Biochem; 2004 Mar; 258(1-2):25-33. PubMed ID: 15030167
[TBL] [Abstract][Full Text] [Related]
18. Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
Chen C; Zhuang Y; Chen X; Chen X; Li D; Fan Y; Xu J; Chen Y; Wu L
Oncotarget; 2017 Feb; 8(6):10025-10036. PubMed ID: 28036294
[TBL] [Abstract][Full Text] [Related]
19. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity.
Honma Y; Okabe-Kado J; Hozumi M; Uehara Y; Mizuno S
Cancer Res; 1989 Jan; 49(2):331-4. PubMed ID: 2910452
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70.
Chakraborty PK; Mustafi SB; Ganguly S; Chatterjee M; Raha S
Cancer Sci; 2008 Jun; 99(6):1109-16. PubMed ID: 18429957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
